MKA Insights

About John

John is a bioprocessing industry veteran who has spent three decades building and leading commercial organizations for some of the world’s largest life sciences companies. His career has been defined by his ability to navigate complex M&A transitions, realign sales teams for better performance, and develop the next generation of sales leaders—making him one of the most experienced bioprocessing sales executives in the industry.

He started his career over 30 years ago as a sales rep at Life Technologies (Invitrogen/Gibco), where he spent nearly two decades progressing through roles of increasing responsibility—eventually becoming National Sales Manager before leaving to join Thermo Fisher Scientific. During his time at Life Technologies, John developed a deep understanding of cell culture products, upstream bioprocessing, and the technical sales process required to serve biopharma and CDMO customers. This foundation would prove invaluable throughout his career as the industry consolidated and companies navigated increasingly complex M&A activity.

At Thermo Fisher Scientific, John served as Director of Western Sales for HyClone cell culture products, managing a team of 10 sales and technical professionals responsible for a $100M+ portfolio. During his tenure, he successfully realigned the team from a product-focused approach to an account-based regional strategy—redirecting efforts toward long-term, high-value opportunities and improving team performance against business expectations. This reorganization required strong leadership, deep customer knowledge, and the ability to change how sales teams operated in the field—skills that would define much of John’s later work.

When Thermo Fisher purchased Life Technologies, the FTC mandated divestiture of certain HyClone products to preserve competition in the cell culture market. John was part of the small leadership team tasked with carving out a competitive, stand-alone cell culture business—delicately unwinding products, customers, employees, and revenue streams that had been integrated into Thermo Fisher’s operations. This was a complex, high-stakes project that required careful planning, clear communication, and the ability to build a business that could operate independently. Once the carve-out was complete, it was sold to GE Healthcare, and John transitioned with the business to ensure continuity and commercial success.

At GE Healthcare, John held several leadership roles focused on integration, business continuity, and capturing deal-model synergies. His responsibilities expanded significantly—from managing a $70M cell culture portfolio to leading a $400M Upstream Bioprocessing portfolio with a team of 55 people. During this period, GE was actively building its life sciences capabilities, and John played a critical role in ensuring that the acquired HyClone business could scale and integrate effectively within GE’s broader portfolio. His work focused on aligning sales strategies, managing team performance, and ensuring that customers experienced minimal disruption during the transition.

When GE divested its Healthcare business to Danaher, John once again navigated a major M&A transition—helping integrate the business into what would become Cytiva. At Danaher, one of John’s critical initiatives was developing a sales force succession plan—ensuring the organization had a pipeline of future leaders and continuity of commercial performance. This work reflected his long-term view of sales leadership: it’s not just about hitting this quarter’s numbers, it’s about building organizations that can sustain performance over time by developing talent, creating clear career paths, and ensuring that institutional knowledge isn’t lost when leaders move on.

Most recently, John served as head of the US Sales Team at ILC Dover (a PE-backed company), where he built a greenfield sales organization to support the company’s go-to-market expansion. This experience brought his career full circle—taking the lessons learned from 30 years at some of the world’s largest bioprocessing companies and applying them to help a smaller, growth-stage business scale its commercial operations.

At MKA Insights, John works with bioprocessing and life sciences clients on sales strategy, territory design, compensation planning, and M&A integration. His deep domain expertise, combined with his hands-on experience navigating multiple divestitures and integrations, makes him uniquely qualified to help companies build and optimize their commercial organizations—whether they’re scaling from startup to growth stage or navigating the complexities of M&A.